GILD
NASDAQ · Biotechnology
Gilead Sciences Inc
$139.37
+3.03 (+2.22%)
GILD News4 articles
Gilead Shares Dip as Yeztugo Sales Outlook Disappoints
Gilead Sciences shares declined as its 2026 sales projection for the HIV prevention drug Yeztugo fell short of some Wall Street estimates. Several brokerages raised price targets following the company's earnings report.
Eli Lilly shares retreat as $2.4B Orna acquisition and China partnership draw scrutiny
Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.
Eli Lilly Shares Dip Following $2.4 Billion Orna Therapeutics Acquisition Announcement
Eli Lilly shares declined 1.3% in after-hours trading after announcing a $2.4 billion acquisition of Orna Therapeutics. Investors are monitoring the deal's impact on Lilly's pipeline and upcoming regulatory decisions.
Gilead Hits 52-Week Peak on FDA Label Expansion for Yescarta, Earnings in Focus
Gilead Sciences reached a 52-week high after the FDA approved a label update for its Yescarta therapy, expanding use to a rare brain lymphoma. The stock's rally comes ahead of the company's quarterly earnings report.